

against the KPC enzyme associated with the restored *in vitro* activity of meropenem. This hypothesis is in agreement with our previous observations that ceftazidime/avibactam restored the susceptibility of most KPC producers to meropenem.¹⁰

Our results showed that clinically achievable concentrations were obtained for meropenem/vaborbactam in association with ceftazidime/avibactam or gentamicin, although low synergistic activity was observed for this combination. Therefore, meropenem/vaborbactam in combination with ceftazidime/avibactam could be considered in patients for whom nephrotoxic drugs should be excluded, for infections due to isolates resistant to one of these novel drugs or for treatments that could potentially cause resistance (e.g. prolonged therapies).

In conclusion, this study suggests that meropenem/vaborbactam in combination with ceftazidime/avibactam might be considered a potential therapeutic option for the treatment of infections caused by KPC-Kp. Further studies are mandatory to evaluate the achievable concentration of meropenem/vaborbactam in association with ceftazidime/avibactam *in vivo*, to define the clinical efficacy of this combination for the treatment of KPC infections and prevent the development of resistance to these novel drugs.

Funding

This work was partially supported by the Emilia-Romagna region.

Transparency declarations

None to declare.

Supplementary data

Figure S1 is available as [Supplementary data](#) at JAC Online.

References

- Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*, a key pathogen set for global nosocomial dominance. *Antimicrob Agents Chemother* 2015; **59**: 5873–84.
- Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I *et al.* Treatment of infections caused by extended-spectrum- β -lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Rev* 2018; **31**: e00079–17.
- Pogue JM, Bonomo RA, Kaye KS. Ceftazidime/avibactam, meropenem/vaborbactam or both? Clinical and formulary considerations. *Clin Infect Dis* 2018; doi:10.1093/cid/ciy576.
- Kazmierczak KM, de Jonge BLM, Stone GG *et al.* *In vitro* activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: iNFORM global surveillance 2012–15. *J Antimicrob Chemother* 2018; **73**: 2782–8.
- Hackel MA, Lomovskaya O, Dudley MN *et al.* *In vitro* activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. *Antimicrob Agents Chemother* 2017; **62**: e01904–17.
- Gaibani P, Campoli C, Lewis RE *et al.* *In vivo* evolution of resistant subpopulations of KPC-producing *Klebsiella pneumoniae* during ceftazidime/avibactam treatment. *J Antimicrob Chemother* 2018; **73**: 1525–9.
- Sun D, Rubio-Aparicio D, Nelson K *et al.* Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2017; **61**: e01694–17.
- Shields RK, Potoski BA, Haidar G *et al.* Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. *Clin Infect Dis* 2016; **63**: 1615–8.
- Gaibani P, Lombardo D, Lewis RE *et al.* *In vitro* activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing *Klebsiella pneumoniae* bloodstream isolates. *J Antimicrob Chemother* 2014; **69**: 1856–65.
- Gaibani P, Lewis RE, Volpe SL *et al.* *In vitro* interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing *Klebsiella pneumoniae* clinical isolates. *Int J Infect Dis* 2017; **65**: 1–3.

J Antimicrob Chemother 2019; **74**: 1459–1461

doi:10.1093/jac/dky565

Advance Access publication 14 January 2019

Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock

Perrin Ngougni Pokem¹, Arnaud Capron^{2†},
Pierre Wallemacq², Paul M. Tulkens¹,
Françoise Van Bambeke¹ and
Pierre-François Laterre^{3*}

¹Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium;

²Department of Clinical Chemistry, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium;

³Department of Critical Care Medicine, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium

*Corresponding author. Tel: +32 2 7642735; E-mail: pierre-francois.laterre@uclouvain.be

†Present address: Sciensano, Department of Quality of Laboratories, Brussels, Belgium.

Sir,
Resistance of Gram-negative pathogens to current antibiotics has revived interest in earlier and often disused molecules for which resistance is still low. Yet, detailed pharmacokinetic/pharmacodynamic data are scarce for these drugs. A typical example is temocillin (6- α -methoxy-ticarclillin), active against most Gram-negative bacteria, which shows stability against a variety

of β -lactamases, including most ESBLs, AmpC and some carbapenemases. Temocillin represents a strategic sparing alternative to carbapenems.¹ There is no EUCAST breakpoint set for temocillin, but in recent surveys, MIC₉₀ values of 8–16 mg/L were reported for ESBL and AmpC producers.^{2,3} The main driver of efficacy of β -lactams is the fraction of time between successive administrations during which their free concentration remains above the MIC for the offending organism. For penicillins, it is generally accepted that this fraction must reach 40% of the dosing interval. However, more demanding targets (such as maintaining unbound concentrations >4 times the MIC for the offending organism) have been advocated for severe infections in critically ill patients⁴ and for preventing the emergence of resistance.⁵ This may require the use of large doses as well as implementing continuous infusion as done routinely for temocillin in our ICU.⁶ Yet, many infections are located deep in tissues, highlighting the importance of antibiotic tissue penetration in the final outcome of the treatment. In this context, we report here the case of a critically ill patient in whom we could measure temocillin concentration in the pancreatic tissue. Written informed consent was obtained from the patient's relatives for collecting samples.

A female in her early fifties was transferred to our ICU from another institution because of severe necrotizing pancreatitis secondary to duodenal perforation after endoscopic retrograde cholangiopancreatography. She received meropenem for >2 weeks for suspicion of a pancreatic infection. In the third week after admission, her condition deteriorated with development of septic shock. A duodenal fistula was documented and blood cultures grew for *Klebsiella pneumoniae* with MICs (Etest) of 12 mg/L for meropenem (categorized as resistant) and 16 mg/L for temocillin. Temocillin was given for 10 days by continuous infusion at a daily dose of 6 g owing to the low susceptibility of the pathogen, even though the patient was under continuous haemofiltration (owing to acute renal failure; glomerular filtration rate = 20 mL/min). Temocillin total and unbound concentrations were quantified in plasma samples collected every 24 h from day 5 to day 9, using a validated LC–tandem MS method.⁷ Bacteraemia had resolved after 10 days of treatment, but surgical debridement was required to remove infected pancreatic tissue, giving us the opportunity to collect a necrotic sample at day 8 and to measure its temocillin content. In brief, the sample was washed in saline, dried at 40°C for 24 h (temocillin stability was >90% in these conditions), homogenized in saline, reconstituted in ethyl acetate containing internal standard (ticarcillin) and phosphate buffer pH 9.2, and centrifuged at 4°C for 5 min at 11 000 g. The organic phase was collected, evaporated and reconstituted in 20 μ L of mobile phase for assay as described for plasma samples,⁷ with a calibration curve using a fragment of porcine pancreas spiked with temocillin and treated by the same procedure.

Mean unbound and total temocillin concentrations in plasma remained stable over time during the sampling period (69.8 ± 5.2 and 112.5 ± 2.9 mg/L, respectively; see Figure 1). These high levels are probably explained by the patient's renal insufficiency. Notably, the unbound concentrations, which were high probably owing to the low plasma protein level (44.6 ± 1.6 g/L; see discussion in Alexandre and Fantin³ and Laterre *et al.*⁶), were continuously >4 times the MIC for the offending organism. Temocillin content in the tissue homogenate was 186 μ g/g, which could be approximated to




Figure 1. Concentration of total (filled circles) and unbound (open circles) temocillin in plasma samples and of total temocillin in pancreatic homogenate (grey squares) collected from a critically ill patient receiving 6 g per day by continuous infusion. Plasma samples were collected from day 5 to day 9 of treatment, and the pancreatic biopsy was collected at day 8. The horizontal broken lines correspond to typical MIC₉₀ values reported in recent surveys for Enterobacteriaceae producing ESBLs (8 and 16 mg/L).

186 mg/L.⁸ Such a high concentration was unexpected, because β -lactams show a low distribution volume (denoting a lack of tissue accumulation), and because necrotic tissue is poorly vascularized. It could be related to the long-lasting exposure of the tissue to stable, elevated serum levels afforded by the continuous infusion, the high unbound plasma concentrations in this patient and the low perfusion of the organ, which could reduce the clearance of the drug if bound to tissue constituents. As we used whole-tissue homogenate, this value represents the mean concentration of drug present extracellularly or intracellularly. In most publications, the temocillin concentrations in tissues and body fluids represent 8%–65% of the total serum concentrations (see Alexandre and Fantin³ for review), but these may not represent values at equilibrium since temocillin was given by discontinuous infusion. Moreover, these studies were not performed in critically ill patients. Finally, total tissue levels could be high owing to low serum protein concentration, resulting in a temocillin equilibrium shift in favour of the tissue. This is of particular importance for drugs with non-linear protein binding⁹ such as temocillin. Thus, although limited to a single case, these data suggest that temocillin may reach therapeutic levels in some tissues and encourage further studies in this area.

Acknowledgements

We are grateful to the on-site nurses for their participation and to M. Vergauwen (Chirurgie Expérimentale et Transplantation; Université catholique de Louvain) for providing us with a sample of porcine pancreas.

Funding

This study was carried out as part of our routine work.

Transparency declarations

P. N. P. is an employee of the Université catholique de Louvain. A. C. was and P. W. and P.-F. L. are employees of the Cliniques universitaires Saint-Luc. P. M. T. was unpaid. F. V. B. is Research Director of the Fonds de la Recherche Scientifique (F.R.S.-FNRS). P. M. T. is an unpaid advisor to Eumedica, the registration holder of temocillin.

References

- 1 Livermore DM, Tulkens PM. Temocillin revived. *J Antimicrob Chemother* 2009; **63**: 243–5.
- 2 Alexandre K, Reveillon-Istin M, Fabre R *et al*. Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods. *J Antimicrob Chemother* 2018; **73**: 1848–53.
- 3 Alexandre K, Fantin B. Pharmacokinetics and pharmacodynamics of temocillin. *Clin Pharmacokinet* 2018; **57**: 287–96.
- 4 Delattre IK, Taccone FS, Jacobs F *et al*. Optimizing β -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective? *Expert Rev Anti Infect Ther* 2017; **15**: 677–88.
- 5 Tam VH, Chang KT, Zhou J *et al*. Determining β -lactam exposure threshold to suppress resistance development in Gram-negative bacteria. *J Antimicrob Chemother* 2017; **72**: 1421–8.
- 6 Laterre PF, Wittebole X, Van de Velde S *et al*. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. *J Antimicrob Chemother* 2015; **70**: 891–8.
- 7 Ngougni Pokem P, Miranda Bastos AC, Tulkens PM *et al*. Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. *Clin Biochem* 2015; **48**: 542–5.
- 8 Caglar V, Kumral B, Uygur R *et al*. Study of volume, weight and size of normal pancreas, spleen and kidney in adults autopsies. *FMAR* 2014; **2**: 63–9.
- 9 Deitchman AN, Singh RSP, Derendorf H. Nonlinear protein binding: not what you think. *J Pharm Sci* 2018; **107**: 1754–60.

J Antimicrob Chemother 2019; **74**: 1461–1463

doi:10.1093/jac/dkz009

Advance Access publication 5 February 2019

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice

Gianmaria Baldin ¹, Arturo Ciccullo ^{1*}, Alberto Borghetti² and Simona Di Giambenedetto^{1,2}

¹Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy; ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

*Corresponding author. E-mail: arturo.ciccullo@gmail.com  orcid.org/0000-0001-5941-883X

Sir,

We read with interest the work by Joly *et al.*¹ on the results of the LAMIDOL trial, showing the high efficacy of the switch strategy with lamivudine plus dolutegravir in virologically suppressed HIV-1-infected patients, after 48 weeks of follow-up. Indeed, this dual regimen has drawn much attention from clinicians and different works focus on this switch strategy.^{2–5} In particular, we agree with the authors on the necessity of further studies exploring this dual regimen in a wider population, with a longer time from HIV diagnosis, past virological failures and/or the presence of the M184V resistance mutation.

Herein we present the findings from a retrospective study that considered HIV-1-infected, virologically suppressed (defined as HIV-RNA <50 copies/mL), adult (≥ 18 years old) patients switching to lamivudine plus dolutegravir in a third-level clinical centre (i.e. a university hospital). This was a single-centre study. We used the Kaplan–Meier estimator to evaluate the time to virological failure (defined as one single HIV-RNA determination ≥ 1000 copies/mL or two consecutive HIV-RNA determinations ≥ 50 copies/mL) and Cox regression analysis to evaluate predictors of virological failure. We also evaluated the proportion of patients maintaining virological suppression at 48, 96 and 144 weeks. The cumulative burden of low-level HIV-RNA was measured via viraemia copy years.⁶ The study was approved by the local Ethics Committee (protocol number 5284/15) and all patients provided signed informed consent to data recording. We analysed 221 patients; 69 (31.2%) were females and the patients had a median age of 51 years (IQR 43–57), a median time from HIV diagnosis of 14 years (IQR 7–20) and a median time of exposure to ART of 11 years (IQR 5–17). A previous AIDS event was experienced by 65 patients (29.4%), while 96 of them (43.4%) had at least one previous virological failure and